Research advances in Peyronie's disease: a comprehensive review on genomics, pathways, phenotypic manifestation, and therapeutic targets.
Open accessThe DOI matches its Crossref record; 155 of the 158 references it cites were found in a registry or an index, and 1 are not checked yet; 58 of the 163 sources its claims cite were checked for support.
Abstract
INTRODUCTION: Penile induration disease, commonly known as Peyronie's disease (PD), is a connective tissue disorder that affects the penis, leading to the development of fibrous plaques, penile curvature, and erectile dysfunction. PD is a common male reproductive system disease with a complex etiology involving multiple genes, signaling pathways, and different phenotypes. OBJECTIVES: The etiology and pathogenesis of PD remain poorly understood, hindering the development of effective treatment strategies. By understanding the underlying mechanisms of PD, we can pave the way for targeted therapies and improved patient outcomes. METHODS: We reviewed the epidemiology and pathophysiology of PD. We performed database searches on Google Scholar, PubMed, Medline, and Web of Science from inception to September 2023. The literature reviewed included priapism guidelines, review articles, current trial studies, and various literature related to PD. RESULTS: This article provides a comprehensive overview of the current research progress on the disease, focusing on its genetic factors, signaling pathways, cellular mechanisms, phenotypic manifestations, and therapeutic targets. It can help identify individuals at higher risk, aid in early detection and intervention, and provide insights into fibrosis and tissue remodeling. It can also reveal potential therapeutic targets, guide accurate diagnoses and treatment strategies, and address the impact of the disease on patients' quality of life. CONCLUSION: By integrating insights from genomics, molecular pathways, clinical phenotypes, and therapeutic potentials, our research aims to achieve a deeper and more comprehensive understanding of PD, propelling the field toward innovative strategies that enhance the lives of those affected by PD. The complex manifestations and pathogenesis of PD necessitate the use of multiple treatment methods for personalized care.
Verified 2026-11-19 · 1 reference not checked yet
Overview
CoChat Summary
TL;DR
This is a narrative review of Peyronie’s disease (PD) that synthesizes genetic, signaling-pathway, phenotypic, and therapeutic literature to explain why PD develops and how it might be better targeted. The paper argues that PD is multifactorial, driven by interacting genetic susceptibility, inflammation, fibrosis, and cellular remodeling pathways, and that current therapies remain limited for preventing fibrosis or reversing erectile dysfunction (ED).
Key findings
- PD is described as affecting approximately 0.4% to 9% of the male population, with higher incidence in certain age groups.
- The review identifies several candidate genetic factors and loci associated with PD, including COL1A1, COL3A1, COL1A2, ALMS1, TIMP1/TIMP2, MMP2/MMP9, and the WNT2 locus; it also cites chromosomal abnormalities in fibroblasts from PD plaques, including abnormalities in chromosomes 7, 8, 17, 18, and X and recurrent Y deletions.
- Multiple signaling pathways are implicated in PD pathogenesis, especially TGF-β, Wnt/β-catenin, PDGF, NF-κB, and also JAK-STAT, MAPK, RhoA/ROCK, and Shh; these pathways converge on fibroblast activation, myofibroblast differentiation, ECM accumulation, and fibrosis.
- The paper summarizes current therapies as imperfect: conservative treatments may help symptoms, but current therapy “does not effectively prevent penile fibrosis or reverse ED,” and newer approaches such as collagenase Clostridium histolyticum, verapamil, pentoxifylline, tadalafil, traction therapy, shockwave therapy, and PRP are discussed as promising but with limitations.
Methods
- Narrative review of the epidemiology and pathophysiology of PD, aimed at integrating genomics, molecular pathways, phenotypic manifestations, and therapeutic targets.
- Database searches were performed in Google Scholar, PubMed, Medline, and Web of Science from inception to September 2023.
- The literature reviewed included guidelines, review articles, current trial studies, and other PD-related publications; the paper also draws on previously reported bioinformatic analyses and cited primary studies.
Limitations
- The paper states that the etiology and pathogenesis remain poorly understood and that the precise interplay and relative contributions of the pathways are still points of contention.
- It also notes that further research is needed to clarify pathway interactions and identify safe and effective therapeutic targets.
- Evident from the text: this is a review, not a primary study, so its conclusions depend on the quality and scope of the cited literature rather than new patient-level data.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
44 Valid · 4 Not valid · 51 Not checked · 62 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Fibrosis in PD not only affects the tunica albuginea but can involve other penile structures, including the erectile tissues (corpora cavernosa) and surrounding connective tissues.76,111”
§ Research advances in Peyronie's disease: a comprehensive review on genomics, pathways, phenotypic manifestation, and therapeutic targets > Fibrosis in penile tissues
What the sources say
- Disputedcites [76] Martin, 2022, Sonic hedgehog signaling in primary culture of human corpora cavernosal tissue from prostatectomy, diabetic, and Peyronie’s patients, J Sex Med sourceExperimental — accuracy not yet measured
The Results (Patient Information) state that a collagenous plaque forms under the tunica in Peyronie’s disease, but the adjacent corpora cavernosal tissue retains normal smooth-muscle and collagen morphology and abundance. The Methods (Patients) likewise describe the corpora cavernosal tissue of these patients as normal, contrary to the claim that PD fibrosis can involve that erectile tissue. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [111] Ferrini, 2010, The genetic inactivation of inducible nitric oxide synthase (iNOS) intensifies fibrosis and oxidative stress in the penile corpora cavernosa in type 1 diabetes, J Sex Med source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Studies have shown that mutations or abnormal expression of the COL1A1 gene are associated with PD.”
§ Research advances in Peyronie's disease: a comprehensive review on genomics, pathways, phenotypic manifestation, and therapeutic targets > Gene mutations and variants associated with the disease
What the sources say
- Could not verifycites [19] Milenkovic, 2022, Single-cell transcriptomics uncover a novel role of myeloid cells and T-lymphocytes in the fibrotic microenvironment in Peyronie’s disease, Eur Urol Focus sourceExperimental — accuracy not yet measured
Our copy of Milenkovic et al. (2021, Eur Urol Focus) never mentions COL1A1 or any gene mutation: searched 'COL1A1', 'collagen type I alpha 1 / gene expression markers', 'genetic risk factors familial susceptibility'. The only collagen-related passages are the Results and limitations summary, which lists COL1A2⁺ merely as a cluster marker for fibroblasts and myofibroblasts, and the Conclusions, which state that 'vascularisation and collagen production are elevated' in chronic PD plaques — neither addresses COL1A1 mutation or abnormal expression as an association with PD. The paper's stated aim (Abstract > Objective) is the immunological signature of PD plaques by IHC and scRNA-Seq, so the claim's genetic point is simply not treated here. (LLM, conf=0.72)
- Partly supportedcites [22] Mohede, 2018, Verteporfin as a medical treatment in Peyronie’s disease, Sex Med sourceExperimental — accuracy not yet measured
The Abstract’s Methods and Results report COL1A1 expression in cells cultured from PD plaques and a significant decrease after verteporfin treatment. That supports a connection between COL1A1 expression and PD plaque fibrosis, but the paper does not report COL1A1 mutations or show that its expression is abnormal relative to tissue without PD. (LLM, conf=0.83)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“A rare nonsynonymous mutation in the ALMS1 gene was identified in 3 men.”
§ Research advances in Peyronie's disease: a comprehensive review on genomics, pathways, phenotypic manifestation, and therapeutic targets > Gene mutations and variants associated with the disease
What the sources say
- Supportedcites [21] Dullea, 2022, Whole-genome sequencing identifies novel heterozygous mutation in ALMS1 in three men with both Peyronie’s and Dupuytren’s disease, Urology source
The Results report rare protein-altering ALMS1 variants in all three individuals, and the Discussion describes three men with rare missense mutations in ALMS1. The paper separately cautions that a specific potentially pathogenic point mutation was validated in only one sample; the claim does not say it was validated in all three. (LLM, conf=0.90)
plainn = 3- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Several studies have identified specific genetic risk loci that may be associated with PD.”
§ Research advances in Peyronie's disease: a comprehensive review on genomics, pathways, phenotypic manifestation, and therapeutic targets > Identified genetic risk loci
What the sources say
- Supportedcites [6] Herati, 2016, The genetic basis of Peyronie disease: a review, Sex Med Rev source
The review’s “Single Nucleotide Polymorphisms Associated with PD and DD” section (page not provided) reports studies associating G915C in TGFβ1 and rs4730775 at the WNT2 locus with PD. These findings support the qualified claim that studies have identified genetic loci that may be associated with PD. (LLM, conf=0.91)
- Not checked — no full text of the sourcecites [11] Somers, 1987, Chromosome abnormalities in Peyronie’s disease, J Urol source
- Not checked — no full text of the sourcecites [12] Guerneri, 1991, Multiple clonal chromosome abnormalities in Peyronie’s disease, Cancer Genet Cytogenet source
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“It is important to note that while genetic predisposition plays a role in disease susceptibility, the development of PD is likely influenced by a combination of genetic, environmental, and various lifestyle factors, such as smoking, alcohol consumption, aging, trauma to the penile tissue, and other systemic diseases, which can interact with genetic susceptibility to trigger the disease.”
§ Research advances in Peyronie's disease: a comprehensive review on genomics, pathways, phenotypic manifestation, and therapeutic targets > Genetic predisposition and family history
What the sources say
- Not checked — no full text of the sourcecites [30] Bjekic, 2006, Risk factors for Peyronie’s disease: a case-control study, BJU Int source
- Partly supportedcites [31] Mitsui, 2022, ABO blood type and risk of Peyronie’s disease in Japanese males, World J Mens Health sourceExperimental — accuracy not yet measured
The Introduction (page not provided) links PD to genetic predisposition, smoking, penile trauma, and systemic conditions; the Results also identify age as an associated factor. The paper does not identify alcohol consumption as a risk factor or say that these factors interact with genetic susceptibility to trigger PD. (LLM, conf=0.86)
- Not checked yetcites [32] Doersch, 2022, The contribution of the immune system to genitourinary fibrosis, Exp Biol Med (Maywood) source
Checked before — its earlier verdict is held back until a new check runs.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
76 more claims · 26 with their cited sources checked
Create a free account to see all 161 claims and to verify the 23 references still open.
- Probably not a substantial claim. 34
- The quote only partly states this claim. 3
- It may state two separate claims as one. 56
Citations
Cites
Hao (2015) · doi:10.1002/14651858 · Cited by 11,321
Cellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495
TGF-β: the master regulator of fibrosis
Meng, X.-M., Nikolic-Paterson, D. J., & Lan, H. Y. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.48 · Cited by 3,528
Crosstalk of reactive oxygen species and NF-κB signaling
Morgan, M. J., & Liu, Z.-G. (2011) · Cell Research · doi:10.1038/cr.2010.178 · Cited by 3,505
The NF- B Family of Transcription Factors and Its Regulation
Oeckinghaus, A., & Ghosh, S. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000034 · Cited by 2,842
Mechanisms of Caspase Activation and Inhibition during Apoptosis
Shi, Y. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00482-3 · Cited by 1,833
Signaling mechanisms of the epithelial-mesenchymal transition
Gonzalez, D. M., & Medici, D. (2014) · Science Signaling · doi:10.1126/scisignal.2005189 · Cited by 1,721
TGF-β and the TGF-β family: context-dependent roles in cell and tissue physiology
Morikawa, M., Derynck, R., & Miyazono, K. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a021873 · Cited by 1,321
Osteoarthritis: pathogenic signaling pathways and therapeutic targets
Yao, Q., Wu, X., Tao, C., Gong, W., Chen, M., Qu, M., Zhong, Y., He, T., Chen, S., & Xiao, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01330-w · Cited by 1,194
The extracellular matrix: tools and insights for the "omics" era
Naba, A., Clauser, K. R., Ding, H., Whittaker, C. A., Carr, S. A., & Hynes, R. O. (2016) · Matrix Biology · doi:10.1016/j.matbio.2015.06.003 · Cited by 1,037
Research works printed but not linked: 1
- Chung, 2020, Peyronie’s disease: what do we know and how do we treat it?, Can J Urol, 27, 11
Cited by
Chung, E., Ziegelmann, M., Lin, H. C., Jenkins, L. C., Broderick, G. A., Moon, D. G., Seyam, R. M., Deveci, S., Morey, A. F., & Levine, L. A. (2025) · Sexual Medicine Reviews · doi:10.1093/sxmrev/qeaf068 · Cited by 11
Current insights and future directions in Peyronie's disease management: A narrative review
Howell, S., Green, T., & Khalafalla, K. M. (2024) · UroPrecision · doi:10.1002/uro2.104 · Cited by 6
Rizzo, R. H. D., Gonzales, G. C., Cortines, H. R., Carvalho, C. C. F., Rizzo, L. D., Faria, M. H. S., Lopes, V. C., Fácio, F. N., Spessoto, L. C. F., & Pereira, A. C. (2024) · Cureus · doi:10.7759/cureus.76242 · Cited by 2
Diversity matters in Peyronie’s disease clinical trials—a systematic review
Lindenbaum, M. M., Ljubetic, B. M., Leelani, N., Khooblall, P., Bole, R., Lundy, S. D., & Bajic, P. (2025) · The Journal of Sexual Medicine · doi:10.1093/jsxmed/qdaf134 · Cited by 2
Metadata
- Authors
- Chi, J., Bi, W., Lou, K., Ma, J., Wu, J., & Cui, Y.
- Affiliations
- Qingdao University (CN)
- Weifang Chinese Medicine Hospital (CN)
- Corresponding author
- Wu, Jitao
- Cui, Yuanshan
- Venue
- Sexual Medicine Reviews
- Publisher
- Oxford University Press (OUP)
- Published
- 2024-03-07
- Volume
- 12
- Issue
- 3
- Pages
- 477-490
- ISSN
- 2050-0513 (ISSN-L)
- 2050-0521
- OpenAlex
- W4392603935
- Semantic Scholar
- fe054a73b54d1fe2bd3554789343d99c433d5de7
- Cited by
- 14
- References
- 154
- Citations by year
- 2026: 7 · 2025: 5 · 2024: 2
- FWCI
- 1.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Sexual Medicine Reviews (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Shandong Natural Science Foundation (ZR2021LSW019)
- National Nature Science Foundation of China (81870525, 82000649)
- Taishan Scholars Program of Shandong Province (tsqn202306403, tsqn201909199)
- Topics
- Health Sciences › Medicine › Rheumatology › Dupuytren's Contracture and Treatments
- Health Sciences › Medicine › Urology › Urological Disorders and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
- Keywords
- Peyronie's disease, penile fibrosis, penile curvature, erectile dysfunction, genetic susceptibility, signaling pathways, fibrosis, tissue remodeling, therapeutic target, disease phenotypes, pathogenesis, priapism
- MeSH terms
- Humans, Male, Penile Induration, Phenotype, Signal Transduction, Genomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Research advances in Peyronie's disease: a comprehensive review on genomics, pathways, phenotypic manifestation, and therapeutic targets. https://app.cochat.ai/papers/10.1093/sxmrev/qeae006
- The paper
- Chi, J., Bi, W., Lou, K., Ma, J., Wu, J., & Cui, Y. (2024). Research advances in Peyronie's disease: a comprehensive review on genomics, pathways, phenotypic manifestation, and therapeutic targets. Sexual Medicine Reviews. https://doi.org/10.1093/sxmrev/qeae006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
